Tests found that the foreign matter does not pose a clinical risk to patients.

Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Shares ...

Near-term headwinds could sink the stock, but there is more to the story.

Amgen has resisted that withdrawal push, prompting the FDA to double down in April with a formal proposal to pull the drug ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The company said it has reached ...

Amgen (AMGN) closed at $366.44 in the latest trading session, marking a -2.06% move from the prior day. The stock's change ...

Amgen has initiated several product recalls in the US for Sensipar (cinacalcet) and Corlanor (ivabradine). The recalls ...

By Puyaan Singh June 29 (Reuters) - The New England Journal of Medicine on Monday retracted an article on a pivotal clinical trial that supported approval of Amgen’s rare-disease drug, citing concerns ...

Amgen has reacted with consternation to the news that treatment with its KRAS inhibitor Lumykras will no longer be funded in ...

A clinical trial used to approve Amgen Inc.’s pill Tavneos was retracted Monday from the New England Journal of Medicine, ...

Amgen recalls 934K bottles of Corlanor and Sensipar due to foreign material and manufacturing deviations, per FDA June 23 report.

By Jonathan Stempel July 1 (Reuters) - A federal judge on Wednesday blocked Colorado from capping the price of Amgen's ...